Ocugen’s COVID-19 Vax Partner, Bharat Biotech shares Phase 3 Interim Results of COVAXIN

 

• Data from 25,800 participants in Phase 3 trial in India, received vaccine or placebo in a 1:1 ratio showed that the vaccine candidate was well tolerated and demonstrated 81% efficacy in preventing COVID-19 in those without prior infection after the second dose.
  
  
• Clinical trial to continue through to final analysis at 130 confirmed cases in order to gather further data and to evaluate the efficacy of COVAXIN in additional secondary study endpoints.

https://www.globenewswire.com/news-release/2021/03/03/2186178/0/en/Ocugen-s-COVID-19-Vaccine-Co-Development-Partner-Bharat-Biotech-shares-Phase-3-Interim-Results-of-COVAXIN-Demonstrates-Efficacy-of-81.html